Martina M.D. Flammer Sells 1,384 Shares of Insmed Incorporated (NASDAQ:INSM) Stock

Insmed Incorporated (NASDAQ:INSM) insider Martina M.D. Flammer sold 1,384 shares of the company’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $68.72, for a total transaction of $95,108.48. Following the completion of the transaction, the insider now owns 100,165 shares of the company’s stock, valued at $6,883,338.80. This represents a 1.36 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Martina M.D. Flammer also recently made the following trade(s):

• On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The shares were sold at an average price of $63.64, for a total value of $392,786.08.
• On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The stock was sold at an average price of $65.91, for a total value of $220,403.04.

Insmed Price Performance

Shares of Insmed stock opened at $72.51 on Friday. The stock has a market capitalization of $12.97 billion, a P/E ratio of -13.06 and a beta of 1.12. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The business’s fifty day moving average price is $71.18 and its 200 day moving average price is $72.51. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $80.53.

Insmed (NASDAQ:INSM) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. The business’s revenue for the quarter was up 18.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.10) EPS. As a group, research analysts anticipate that Insmed Incorporated will post -5.44 earnings per share for the current year.

Institutional Investors Weigh In On Insmed

Several institutional investors have recently bought and sold shares of INSM. V Square Quantitative Management LLC purchased a new position in shares of Insmed in the 3rd quarter valued at $30,000. GAMMA Investing LLC increased its holdings in Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 224 shares in the last quarter. Exchange Traded Concepts LLC increased its holdings in Insmed by 522.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 627 shares in the last quarter. Blue Trust Inc. raised its position in Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,879 shares during the period. Finally, JCIC Asset Management Inc. acquired a new position in shares of Insmed during the third quarter worth about $133,000.

Analyst Upgrades and Downgrades

INSM has been the topic of a number of recent research reports. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a report on Friday, November 22nd. Bank of America lifted their price objective on shares of Insmed from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, October 9th. Truist Financial reiterated a “buy” rating and set a $105.00 target price (up previously from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Insmed has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.